| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-07 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-05 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |